A Critical Shot in the Arm: US Tackles Doctor Shortage with New Medical Residencies

A Lasting Legacy: UnitedHealthcare and Optum Launch Annual Week of Service in Honor of Brian Thompson

The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices

ASH 2025: Glimmers of Hope and Big Strides in Blood Disorders

A Glimmer of Hope: Syndax's Novel AML Drug Shines Bright at ASH Meeting

Beyond the Hype: Rediscovering True Intimacy with the 'Warm Sex' Approach

A Sweeping Review: CDC's ACIP Panel Takes a Hard Look at the Entire Childhood Vaccine Schedule

A New Era for Public Health: CDC Panel Greenlights Universal Hepatitis B Vaccination

Vinay Prasad Sounds the Alarm: Media Missteps and Harvard’s Choices Are Hurting Biotech

The Pharmaceutical Pulse: A Year-End Reflection on Innovation, Politics, and Public Trust in 2025

Poll Reveals Stark Reality: 1 in 4 ACA Users May Lose Coverage if Subsidies Vanish

A Notable Shift: Dr. Theresa Michele Steps Down from FDA's Nonprescription Drug Leadership

Pharma's Unfolding Drama: 340B Clashes, Vaccine Progress, and Cancer Innovation

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

A New Era for Research Funding: NIH Ditches Paylines for a More Holistic Approach

A Vital Step Forward: Sarepta's Duchenne Drug Secures Key Testing Clearance

A New Hope for Kidney Disease Patients? FDA Greenlights Voyxact, But Pricing Questions Linger

Another Heartbreak in the Alzheimer's Fight: J&J's Posdinemab Stumbles

A Tragic First: Alpha-Gal Syndrome, the Tick-Borne Meat Allergy, Claims a Life

Shifting Sands of Science: How a Trump-Era NIH Policy Reshaped Grant Funding

When Leadership Takes the Reins: Unpacking the FDA's Unusual Priority Voucher Vote

The Evolving Landscape of Biotech Innovation and Investment

The FDA's Golden Ticket: A Moral Maze in Drug Development

The Human Face of AI: How Recursion Pharma and Najat Khan Are Redefining Drug Discovery

The Unseen Hand: WuXi AppTec's Unstoppable Ascent Amidst Global Scrutiny

The Siren Song of Scale: Why Big Pharma's Mega-Mergers So Often Fall Flat

Dragon's Roar in the Lab: How China's Biotech Ambitions Are Quietly Reshaping Global Pharma

The Art of the Barely-There: Is 'Shallowing' the New Frontier of Sexual Pleasure?

The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown

The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety

That Old Familiar Story: Daylight Saving Time, Stuck in Congressional Limbo (Again!)

A Whisper Becomes a Roar: Unpacking the Turmoil at FDA's Biologics Hub

The Unlikely Turnaround: How One Healthcare Innovator Mastered the Art of Cost Control

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

The Great Biotech Reckoning: Moderna's Wild Ride from Pandemic Hero to Post-COVID Crossroads

Biotech's Pulse Check: AI Rises, a Cancer Test Stumbles, and a Rare Disease Shines

The Great Biotech Reckoning: Can Washington and Beijing Find Common Ground (Or Just More Friction)?

The Ozempic Paradox: When a Brand's Triumph Threatens Its Very Name

The Shifting Pulse: Could Dr. Casey Means Reshape America's Health as Surgeon General?